Avectas
Avectas is a cell engineering technology company that enables drug developers to manufacture potent engineered cell therapies.
Avectas has raised €27M across 2 funding rounds from 1 investor, most recently a Series C round in Apr 2020. Based in Dublin, Ireland; founded 2010; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€27M
€27,244,332
Funding rounds
2
Investors
1
distinct backers
Active since
2019-04
latest 2020-04
Funding by year
EUR raised per yearAvectas — funding by year — interactive chart.
Data table
| Avectas — funding by year | |
|---|---|
| 2019 | €8.9M |
| 2020 | €18M |
Signals
High confidenceRaise-next likelihood13
base rate 50% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▲ High-conviction backers
Exit likelihood7
base rate 11% (2+ rounds)
- ▼ Old (16y) — past typical exit age
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-04-16 | Series C | €18M | Seamus Mulligan | View deal → |
| 2019-04-01 | Other | €8.9M | Seamus Mulligan | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Wayflyer€2.1BIreland · E-commerce
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
Global coverage: FundingData